237
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Idiopathic retroperitoneal fibrosis: a cross-sectional study of 142 Chinese patients

, , , , &
Pages 198-205 | Accepted 31 Jul 2017, Published online: 08 Dec 2017

References

  • Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet 2006;367:241–51.
  • Vaglio A, Maritati F. Idiopathic retroperitoneal fibrosis. J Am Soc Nephrol 2016;27:1880–9.
  • Mitchinson MJ. Chronic periaortitis and periarteritis. Histopathology 1984;8:589–600.
  • Parums DV, Brown DL, Mitchinson MJ. Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med 1990;114:383–7.
  • Kamisawa T, Funata N, Hayashi Y, Tsuruta K, Okamoto A, Amemiya K, et al. Close relationship between autoimmune pancreatitis and multifocal fibrosclerosis. Gut 2003;52:683–7.
  • Kardar AH, Kattan S, Lindstedt E, Hanash K. Steroid therapy for idiopathic retroperitoneal fibrosis: dose and duration. J Urol 2002;168:550–5.
  • Paz Z, Shoenfeld Y. Antifibrosis: to reverse the irreversible. Clin Rev Allergy Immunol 2010;38:276–86.
  • Vaglio A, Palmisano A, Alberici F, Maggiore U, Ferretti S, Cobelli R, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet 2011;378:338–46.
  • van Bommel EF, Pelkmans LG, van Damme H, Hendriksz TR. Long-term safety and efficacy of a tamoxifen-based treatment strategy for idiopathic retroperitoneal fibrosis. Eur J Intern Med 2013;24:444–50.
  • Caiafa RO, Vinuesa AS, Izquierdo RS, Brufau BP, Ayuso Colella JR, Molina CN. Retroperitoneal fibrosis: role of imaging in diagnosis and follow-up. Radiographics 2013;33:535–52.
  • Vaglio A, Versari A, Fraternali A, Ferrozzi F, Salvarani C, Buzio C. (18)F-fluorodeoxyglucose positron emission tomography in the diagnosis and followup of idiopathic retroperitoneal fibrosis. Arthritis Rheum 2005;53:122–5.
  • Rossi GM, Rocco R, Accorsi Buttini E, Marvisi C, Vaglio A. Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease. Intern Emerg Med 2017;12:287–99.
  • Chaiton MO, Cohen JE, McDonald PW, Bondy SJ. The Heaviness of Smoking Index as a predictor of smoking cessation in Canada. Addict Behav 2007;32:1031–42.
  • Borland R, Yong HH, O’Connor RJ, Hyland A, Thompson ME. The reliability and predictive validity of the Heaviness of Smoking Index and its two components: findings from the International Tobacco Control Four Country study. Nicotine Tob Res 2010;12:S45–50.
  • Wang H. [Analysis of coronary angiography in elderly patients with coronary heart disease with high smoking index], in Chinese. Chin J Geriatr Care 2014;12:46.
  • Huang H, Chen A, Liu C, Qian A, LV Y. [Effects of smoking on platelet aggregation rate and high-sensitivity C-reactive protein in hypertensive patients], in Chinese. Prev Treat Cardio-Cerebral-Vascular Dis 2013;13:210–3.
  • Scheel PJ Jr., Feeley N. Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation. Medicine (Baltimore) 2009;88:202–7.
  • Yachoui R, Sehgal R, Carmichael B. Idiopathic retroperitoneal fibrosis: clinicopathologic features and outcome analysis. Clin Rheumatol 2016;35:401–7.
  • van Bommel EF, Jansen I, Hendriksz TR, Aarnoudse AL. Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore) 2009;88:193–201.
  • Scheel PJ, Feeley N. Retroperitoneal fibrosis. Rheum Dis Clin North Am 2013;39:365–81.
  • Li S, Meng L, Chiolero A, Ma C, Xi B. Trends in smoking prevalence and attributable mortality in China, 1991-2011. Prev Med 2016;93:82–7.
  • Goldoni M, Bonini S, Urban ML, Palmisano A, De PG, Galletti E, et al. Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis: a case-control study. Ann Intern Med 2014;161:181–8.
  • George V, Tammisetti VS, Surabhi VR, Shanbhogue AK. Chronic fibrosing conditions in abdominal imaging. Radiographics 2013;33:1053–80.
  • Vaglio A. Retroperitoneal fibrosis: new insights into clinical presentation and diagnosis. Medicine (Baltimore) 2009;88:208–10.
  • Cronin CG, Lohan DG, Blake MA, Roche C, McCarthy P, Murphy JM. Retroperitoneal fibrosis: a review of clinical features and imaging findings. AJR Am J Roentgenol 2008;191:423–31.
  • Palmisano A, Urban ML, Corradi D, Cobelli R, Alberici F, Maritati F, et al. Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis? Rheumatology (Oxford) 2015;54:2004–9.
  • Scheel PJ Jr., Feeley N, Sozio SM. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. Ann Intern Med 2011;154:31–6.
  • Binder M, Uhl M, Wiech T, Kollert F, Thiel J, Sass JO, et al. Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. Ann Rheum Dis 2012;71:311–12.
  • Degesys GE, Dunnick NR, Silverman PM, Cohan RH, Illescas FF, Castagno A. Retroperitoneal fibrosis: use of CT in distinguishing among possible causes. AJR Am J Roentgenol 1986;146:57–60.
  • Salvarani C, Pipitone N, Versari A, Vaglio A, Serafini D, Bajocchi G, et al. Positron emission tomography (PET): evaluation of chronic periaortitis. Arthritis Rheum 2005;53:298–303.
  • Zen Y, Onodera M, Inoue D, Kitao A, Matsui O, Nohara T, et al. Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol 2009;33:1833–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.